Aprea Therapeutics, Inc. (APRE) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 18, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Aprea Therapeutics, Inc. (APRE), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Aprea Therapeutics, Inc., analysts forecast revenue rising from 293,667 in 2025 to 66.65M in 2030; the average estimate for 2030 earnings per share is −0.69; 4 analysts contribute to these figures. These are forecasts published by analysts, not results.
Revenue forecast (reporting currency)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Aprea Therapeutics, Inc. (APRE) forecast — frequently asked questions
What are analysts forecasting for Aprea Therapeutics, Inc.'s earnings?
The average analyst estimate for Aprea Therapeutics, Inc. (APRE) earnings per share in 2030 is -0.69, with individual estimates between -0.69 and -0.69.
How much revenue is Aprea Therapeutics, Inc. expected to make?
Analysts forecast Aprea Therapeutics, Inc. (APRE) revenue of 66.65M in 2030, based on 2 published estimates.
How many analysts cover APRE?
4 analysts contribute estimates for Aprea Therapeutics, Inc. (APRE). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.